Tesamorelin carries exactly one FDA-approved indication: the reduction of excess visceral abdominal fat in adults living with HIV who have lipodystrophy. The FDA granted that approval in November 2010, and the drug reached the market as Egrifta, a once-daily subcutaneous injection. Every use outside that single population, including general weight loss, bodybuilding, and anti-aging, sits off-label and outside the evidence the agency reviewed.
Tesamorelin holds a single FDA indication, granted in November 2010 under the brand Egrifta, for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
The one indication reads, in substance, as a treatment to reduce excess visceral abdominal fat in adult patients with HIV who have lipodystrophy, and every word in that phrase narrows the scope. Visceral abdominal fat refers specifically to adipose tissue packed deep inside the abdominal cavity around the liver and intestines, not the subcutaneous fat that sits just under the skin. The literature is precise that the therapy targets this deep depot and was never shown to reliably reduce subcutaneous fat, which in HIV lipodystrophy is often the loss patients are already dealing with.
The indication is drawn tightly to one condition, excess visceral abdominal fat in adults with HIV-associated lipodystrophy, and deliberately excludes subcutaneous fat because that is where the trials and the drug's mechanism showed effect.
The FDA approved tesamorelin in November 2010, and it launched under the brand name Egrifta, with tesamorelin acetate as the active molecule. The original product required daily reconstitution of a lyophilized powder before subcutaneous injection, and because the approved population is small and clinically specific, the drug has occupied a specialty niche distributed through specialty pharmacy channels rather than a mass market. A reformulated version marketed as Egrifta SV was later introduced to simplify preparation and improve stability, but the underlying indication did not change with it.
Tesamorelin was approved in November 2010 and first marketed as Egrifta, with a later Egrifta SV reformulation that simplified preparation without broadening the original HIV-lipodystrophy indication.
Three criteria define the covered population, and the record is clear that all three must be met: the patient must be an adult, must be living with HIV, and must have lipodystrophy with excess visceral abdominal fat. Adolescents and children fall outside the approval because pediatric safety and efficacy were not established, and an HIV-negative person with high visceral fat is likewise outside the indication even though visceral adiposity is common in the general population. Several comorbidities also remove a patient from the eligible group or demand caution, since the population was drawn to match exactly where the controlled trials demonstrated benefit.
The approved population is limited to adults living with HIV who have lipodystrophy with excess visceral abdominal fat, excluding children, HIV-negative individuals, and, by contraindication, patients with active malignancy or pregnancy.
Approval rested on two large randomized, double-blind, placebo-controlled Phase 3 trials in adults with HIV and abdominal fat accumulation, with the percentage change in visceral adipose tissue as the primary endpoint. That reduction was quantified objectively using single-slice abdominal CT imaging at the L4 to L5 vertebral level, a standard technique for isolating the visceral compartment from subcutaneous fat. A telling detail from the trial program is that when patients stopped the drug the visceral fat tended to return, which framed tesamorelin as a chronic therapy for an ongoing condition rather than a one-time correction.
In two Phase 3 trials, patients on tesamorelin achieved roughly a 15 to 18 percent reduction in visceral adipose tissue over about six months versus placebo, measured by L4-L5 CT imaging, with the fat returning after withdrawal.
The distinction matters because HIV-associated visceral fat accumulation is documented as a metabolic syndrome with its own causes and risks, not a lifestyle-driven weight problem. In people living with HIV the redistribution has been tied to a combination of the chronic infection, immune and inflammatory changes, and the long-term effects of certain antiretroviral regimens, all of which push fat into the deep abdominal compartment even in patients who are not overweight overall. That location is what carries the danger, because visceral fat is metabolically active in a way subcutaneous fat is not, releasing free fatty acids and inflammatory signals into the portal circulation and standing independently associated with insulin resistance, dyslipidemia, and elevated cardiovascular risk.
HIV-associated visceral fat accumulation is documented as a distinct metabolic syndrome driven by infection, inflammation, and antiretroviral therapy rather than overeating, and its portal-circulation activity carries independent cardiometabolic risk that ordinary subcutaneous fat does not.
Several popular assumptions about tesamorelin are contradicted by the label, and the gap between mechanism and evidence is where the risk lives. It is not approved for general weight loss, since the indication targets a specific fat depot in a specific disease and was never studied as a diet aid; it is not approved for bodybuilding, muscle building, or athletic performance despite fitness-circle marketing that leans on its growth-hormone-releasing mechanism; and it is not approved as an anti-aging or longevity therapy even though the same mechanism gets promoted that way in the wellness market. These reputations persist because anything that raises growth hormone attracts interest from people chasing leanness, muscle, or youthfulness, which lets the mechanism outrun the evidence in popular perception.
Tesamorelin is not FDA-approved for general weight loss, bodybuilding or athletic performance, or anti-aging, and pursuing those unapproved uses forfeits the FDA-reviewed safety framework while the glucose-metabolism and theoretical tumor-growth concerns still apply.
An approved indication and off-label use sit on opposite sides of a regulatory line, and the difference clears up much of the confusion around a narrow-label drug. An FDA-approved indication certifies that the agency reviewed controlled evidence and concluded the drug is safe and effective for a defined use in a defined population, and it is the only claim a manufacturer is legally allowed to promote. Off-label prescribing is when a licensed clinician prescribes an approved drug outside that stamped indication; it is legal and sometimes appropriate medical practice, but the FDA has not vetted that use, so the responsibility shifts onto the prescriber and patient without the evidentiary backing the indication provides.
| Dimension | Approved indication | Off-label prescribing |
|---|---|---|
| FDA review | Controlled evidence vetted for the use | Use not vetted by the FDA |
| Manufacturer promotion | Permitted for the approved claim | Legally barred |
| Insurance coverage | Commonly covered | Often not covered; cost lands on the patient |
| Responsibility | Backed by the reviewed indication | Rests on prescriber and patient judgment |
An FDA-approved indication reflects agency-vetted controlled evidence and is the only use a manufacturer may promote or insurers reliably cover, whereas off-label prescribing is legal clinician-directed use the FDA has not reviewed, shifting responsibility onto prescriber and patient.
The approval came wrapped in a set of limitations that define how the drug can be used safely, and the record centers them on the growth-hormone mechanism. Tesamorelin is contraindicated in pregnancy, in patients with active malignancy, and in those with disruption of the hypothalamic-pituitary axis from surgery, radiation, or trauma, and it is not to be given to anyone with known hypersensitivity to the compound. Because it works by raising the body's own growth hormone, the label cautions that it could stimulate the growth of existing or occult tumors, which is why active cancer rules the drug out, and it flags glucose-metabolism effects that call for periodic monitoring of glucose and hemoglobin A1c.
The label contraindicates tesamorelin in pregnancy, active malignancy, and hypothalamic-pituitary axis disruption, and because its growth-hormone mechanism raises tumor-growth and glucose-metabolism concerns, it requires monitoring of blood glucose, hemoglobin A1c, and IGF-1 during use.
Educational use only. This article describes what the published scientific and clinical literature reports about Tesamorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
